



PSMA PET/CT Beyond the Images: The Imager's and Clinicians Perspective

Monday May 30, 2022

14:00-15:30 PT • 17:00-18:30 ET • 18:00-19:30 AT

PROGRAM CHAIR:



Bobby Shayegan

Chair,
CUA Guidelines Committee

Update of the Canadian Landscape

FEATURING GUEST SPEAKER:



Stefano Fanti

Professor of Diagnostic Imaging
Director, Nuclear Medicine Division
and PET Unit, The Policlinico S. Orsola,
Director, Specialty School of Nuclear
Medicine, University of Bologna

Imaging and RLT context in Europe

INVITED SPEAKERS AND CANADIAN GUIDELINE AUTHORS:



Katherine Zukotynski

Associate Professor,
McMaster University

Technology introduction



Frédéric Pouliot

Associate Professor,
Université Laval

What we know and do not know
from prospective PSMA imaging
trials and the impact on outcomes



Rebecca Lo bue

General Manager, Oncidium foundation

Introducing the Oncidium foundation:
supporting the development of
radiotheranostics for cancer care
to enhance patient access, globally.
5 minutes



Odile Jaume

CEO ICPO Foundation

Improve Education and Infrastructure,
Expand Patient Access to Theranostics
in Precision Oncology
5 minutes

OBJECTIVES

Describe the several PSMA-targeting tracers and PET/CT technology (SUVmax, SUV mean, etc.)

Describe the accuracy of PSMA-PET/CT for staging and re-staging prostate cancer based on best prospective studies

Understand the basis of PSMA radioligand therapy and the trials in metastatic prostate cancers

Free sign up >> cua.org/upcoming-events

Supported by:



Oncidium
foundation



NOVARTIS



Claim Section 1
Group Learning Credits

cua.org